It was a black Friday indeed for Ocugen, which revealed in the early morning hours after Thanksgiving that the FDA placed a clinical hold on its COVID-19 vaccine.
The efficacy of Merck’s COVID-19 antiviral has fallen sharply. While most Americans were sleeping off Thanksgiving, Merck revealed the relative risk reduction fell from 50% to 30% in the final…
An MD Anderson team discovered melanoma or lung cancer patients who took antihistamines and checkpoint inhibitors at the same time had significantly better outcomes than did those who did not take the…
Blueprint Medicines knows a thing or two about lung cancer, with one approved medicine already in the bag through a partnership with Roche. Now, the biopharma is making a $250 million play to add…
As Fierce Biotech reported out the aftermath of the controversial approval of Biogen’s Aduhelm, we discovered a common thread at many of the top pharma companies who are working on the most advanced…
Edwards Lifesciences introduced TAVR to the U.S. back in November 2011 when FDA approved its Sapien heart valve for patients with aortic stenosis who were too sick to undergo open heart surgery. This…
Quell Therapeutics’ $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate as way to prevent organ rejection in liver…
As GE prepares to spin off its healthcare business into a separate entity, the soon-to-be standalone company is forging ahead in its quest to develop a broad range of artificial intelligence tools…
With the omicron variant on the horizon, diagnostic companies are racing to determine whether the coronavirus’ latest mutations will hinder the performance of their screening tests. Companies…
Blueprint Medicines is paying $250 million up front to acquire Lengo Therapeutics, developer of targeted cancer therapies. The startup’s lead drug candidate is on track to begin human testing in non…
